Development status: Approved, off-patent

Combination therapy

Mechanism of Action/Target pathogen: Binds irreversibly to beta-lactamases, mainly class A enzymes. No intrinsic antibacterial activity except some antibacterial activity against Acinetobacter

Additional information: Streptomyces natural product. Only available as a combination product, oral and parenteral application